CoChat
Sign Up
Cited by 885

The DOI matches its Crossref record.

Cystic fibrosis

Ratjen, Felix, Döring, Gerd·2003·The Lancet
DOI 10.1016/s0140-6736(03)12567-6
Open this paper in CoChat — free account

Abstract

Cystic fibrosis is the most common autosomal recessive disorder in white people, with a frequency of about 1 in 2500 livebirths. Discovery of the mutated gene encoding a defective chloride channel in epithelial cells--named cystic fibrosis transmembrane conductance regulator (CFTR)--has improved our understanding of the disorder's pathophysiology and has aided diagnosis, but has shown the disease's complexity. Gene replacement therapy is still far from being used in patients with cystic fibrosis, mostly because of difficulties of targeting the appropriate cells. Life expectancy of patients with the disorder has been greatly increased over past decades because of better notions of symptomatic treatment strategies. Here, we summarise advances in understanding and treatment of cystic fibrosis, focusing on pulmonary disease, which accounts for most morbidity and deaths.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)12567-6

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 136

  1. Riordan, 1989, Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA, Science, 245, 1066, 10.1126/science.2475911 · DOI · Paper page
  2. Rommens, 1989, Identification of the cystic fibrosis gene: chromosome walking and jumping, Science, 245, 1059, 10.1126/science.2772657 · DOI
  3. Zielinski, 1991, Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator, Genomics, 10, 241
  4. Collins, 1992, Cystic fibrosis: molecular biology and therapeutic implications, Science, 256, 774, 10.1126/science.1375392 · DOI
  5. Vankeerberghen, 2002, The cystic fibrosis transmembrane conductance regulator: an intriguing protein with pleiotropic functions, J Cystic Fibrosis, 1, 13, 10.1016/S1569-1993(01)00003-0 · DOI
  6. 1993, Correlation between genotype and phenotype in cystic fibrosis, N Engl J Med, 329, 1308, 10.1056/NEJM199310283291804 · DOI
  7. Morral, 1994, The origin of the major cystic fibrosis mutation (delta F508) in European populations, Nat Genet, 7, 169, 10.1038/ng0694-169 · DOI
  8. Lester, 1994, Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population, Pediatrics, 93, 114, 10.1542/peds.93.1.114 · DOI
  9. Bronsveld, 2001, Chloride conductance and genetic background modulate the cystic fibrosis phenotype of Delta F508 homozygous twins and siblings, J Clin Invest, 108, 1705, 10.1172/JCI12108 · DOI
  10. Aron, 1999, HLA class II polymorphism in cystic fibrosis: a possible modifier of pulmonary phenotype, Am J Respir Crit Care Med, 159, 1464, 10.1164/ajrccm.159.5.9807046 · DOI
  11. Grasemann, 2000, Airway NO levels in CF patients are related to a polymorphism in the neuronal NO synthase (NOS1) gene, Am J Respir Crit Care Med, 162, 2172, 10.1164/ajrccm.162.6.2003106 · DOI
  12. Döring, 1994, Allotypes of alpha1-antitrypsin in cystic fibrosis patients homozygous and heterozygous for delta F508, Pediatr Pulmonol, 18, 3, 10.1002/ppul.1950180104 · DOI
  13. Mahadeva, 2001, Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis, Thorax, 56, 53, 10.1136/thorax.56.1.53 · DOI
  14. Garred, 1999, Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis, J Clin Invest, 104, 431, 10.1172/JCI6861 · DOI
  15. Büscher, 2002, β 2-adrenoreceptor polymorphisms as modifiers of lung disease in cystic fibrosis, Pharmacogenetics, 12, 347, 10.1097/00008571-200207000-00002 · DOI
  16. Zielenski, 1999, Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13, Nat Genet, 22, 128, 10.1038/9635 · DOI
  17. Boucher, 1988, Evidence for reduced Cl-and increased Na+ permeability in cystic fibrosis human primary cell cultures, J Physiol, 404, 77, 10.1113/jphysiol.1988.sp017322 · DOI
  18. Schwiebert, 1998, Chloride channel and chloride conductance regulator domains of CFTR, the cystic fibrosis transmembrane conductance regulator, Proc Natl Acad Sci USA, 95, 2674, 10.1073/pnas.95.5.2674 · DOI
  19. Reddy, 1999, Activation of the epithelial Na+ channel (ENaC) requires CFTR Cl- channel function, Nature, 402, 301, 10.1038/46297 · DOI
  20. Knowles, 1991, Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis, N Engl J Med, 325, 533, 10.1056/NEJM199108223250802 · DOI
  21. Quinton, 2001, The neglected ion: HCO3–, Nat Med, 7, 292, 10.1038/85429 · DOI
  22. Khan, 1995, Early pulmonary inflammation in infants with cystic fibrosis, Am J Respir Crit Care Med, 151, 1075
  23. Zahm, 1997, Early alterations in airway mucociliary clearance and inflammation of the lamina propria in CF mice, Am J Physiol, 272, C853, 10.1152/ajpcell.1997.272.3.C853 · DOI
  24. Tirouvanziam, 2000, Inflammation and infection in naive human cystic fibrosis airway grafts, AmJ Respir Cell Mol Biol, 23, 121, 10.1165/ajrcmb.23.2.4214 · DOI
  25. Armstrong, 1997, Lower airway inflammation in infants and young children with cystic fibrosis, Am J Respir Crit Care Med, 156, 1197, 10.1164/ajrccm.156.4.96-11058 · DOI
  26. Bonfield, 1995, Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis, Am J Respir Cell Mol Biol, 13, 257, 10.1165/ajrcmb.13.3.7544594 · DOI
  27. Chmiel, 1999, IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice, Am J Respir Crit Care Med, 160, 2040, 10.1164/ajrccm.160.6.9901043 · DOI
  28. Poschet, 2001, Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung, Proc Natl Acad Sci USA, 98, 13972, 10.1073/pnas.241182598 · DOI
  29. Imundo, 1995, Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface, Proc Natl Acad Sci USA, 92, 3019, 10.1073/pnas.92.7.3019 · DOI
  30. Pier, 1996, Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections, Science, 271, 64, 10.1126/science.271.5245.64 · DOI
  31. Smith, 1996, Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid, Cell, 85, 229, 10.1016/S0092-8674(00)81099-5 · DOI
  32. Widdicombe, 2001, Altered NaCl concentration of airway surface liquid in cystic fibrosis, Pflügers Arch Eur J Physiol, 443, S8
  33. Bals, 1999, Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model, J Clin Invest, 103, 1113, 10.1172/JCI6570 · DOI
  34. Jayaraman, 2001, Noninvasive in vivo fluorescence measurement of airway-surface liquid depth, salt concentration, and pH, J Clin Invest, 107, 317, 10.1172/JCI11154 · DOI
  35. Matsui, 1998, Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease, Cell, 95, 1005, 10.1016/S0092-8674(00)81724-9 · DOI
  36. Worlitzsch, 2002, Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients, J Clin Invest, 109, 317, 10.1172/JCI0213870 · DOI · Paper page
  37. Mathee, 1999, Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung, Microbiology, 145, 1349, 10.1099/13500872-145-6-1349 · DOI
  38. Konstan, 1994, Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation, Am J Respir Crit Care Med, 150, 448, 10.1164/ajrccm.150.2.8049828 · DOI
  39. Kopelman, 1985, Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis, N Engl J Med, 312, 329, 10.1056/NEJM198502073120601 · DOI
  40. Fried, 1991, The cystic fibrosis gene and resting energy expenditure, J Pediatr, 119, 913, 10.1016/S0022-3476(05)83042-2 · DOI
  41. Lanng, 1994, Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications, Acta Paediatr, 83, 72, 10.1111/j.1651-2227.1994.tb12956.x · DOI
  42. Holl, 1997, Insulin resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis patients, J Pediatr Gastroenterol Nutr, 25, 188, 10.1097/00005176-199708000-00010 · DOI
  43. Dodge, 1995, Male fertility in cystic fibrosis, Lancet, 346, 587, 10.1016/S0140-6736(95)91431-5 · DOI
  44. Kopito, 1973, Water and electrolytes in cervical mucus from patients with cystic fibrosis, Fertil Steril, 24, 512, 10.1016/S0015-0282(16)39790-4 · DOI
  45. Rosenstein, 1998, The diagnosis of cystic fibrosis: a consensus statement, J Pediatr, 132, 589, 10.1016/S0022-3476(98)70344-0 · DOI
  46. Stern, 1997, Current concepts: the diagnosis of cystic fibrosis, N Engl J Med, 336, 487, 10.1056/NEJM199702133360707 · DOI
  47. Wilmott, 1998, Making the diagnosis of cystic fibrosis, J Pediatr, 132, 563, 10.1016/S0022-3476(98)70337-3 · DOI
  48. Veeze, 1991, Ion transport abnormalities in rectal suction biopsies from children with cystic fibrosis, Gastroenterology, 101, 398, 10.1016/0016-5085(91)90017-F · DOI
  49. Bush, 2000, Time to think again: cystic fibrosis is not an “all or none” disease, Pediatr Pulmonol, 30, 139, 10.1002/1099-0496(200008)30:2<139::AID-PPUL9>3.0.CO;2-H · DOI
  50. Barbero, 1966, Stool trypsin and chymotrypsin: value in the diagnosis of pancreatic insufficiency in cystic fibrosis, Am J Dis Child, 112, 536, 10.1001/archpedi.1966.02090150080005 · DOI
  51. Phillips, 1999, Faecal elastase 1: a marker of exocrine pancreatic insufficiency in cystic fibrosis, Ann Clin Biochem, 36, 739, 10.1177/000456329903600606 · DOI
  52. Gharib, 1964, Paranasal sinuses in cystic fibrosis: incidence of roentgen abnormalities, Am J Dis Child, 108, 499, 10.1001/archpedi.1964.02090010501009 · DOI
  53. Dörk, 1997, Distinct spectrum of CFTR mutations in congenital absence of vas deferens, Hum Genet, 100, 365, 10.1007/s004390050518 · DOI
  54. Merelle, 2001, Newborn screening for cystic fibrosis (Cochrane Review), Cochrane Database Syst Rev, 3, CD001402
  55. Scotet, 2000, Neonatal screening for cystic fibrosis in Brittany, France: assessment of 10 years' experience and impact on prenatal diagnosis, Lancet, 356, 789, 10.1016/S0140-6736(00)02652-0 · DOI
  56. Farrell, 1997, Nutritional benefits of neonatal screening for cystic fibrosis, N Engl J Med, 337, 963, 10.1056/NEJM199710023371403 · DOI
  57. Farrell, 2001, Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth, Pediatrics, 107, 1, 10.1542/peds.107.1.1 · DOI
  58. Elborn, 1996, Nutrition and survival in cystic fibrosis, Thorax, 51, 971, 10.1136/thx.51.10.971 · DOI
  59. Farrell, 1997, Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis, Pediatrics, 100, E2, 10.1542/peds.100.5.e2 · DOI
  60. Flotte, 2001, Gene therapy in cystic fibrosis, Chest, 120, 124S, 10.1378/chest.120.3_suppl.124S · DOI
  61. Knowles, 1995, A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis, N Engl J Med, 333, 823, 10.1056/NEJM199509283331302 · DOI
  62. Alton, 1999, Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial, Lancet, 353, 947, 10.1016/S0140-6736(98)06532-5 · DOI
  63. Zabner, 1996, Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis, J Clin Invest, 97, 1504, 10.1172/JCI118573 · DOI
  64. Hamilton, 2001, Gentamicin in pharmocogenetic approach to treatment of cystic fibrosis, Lancet, 358, 2014, 10.1016/S0140-6736(01)07138-0 · DOI
  65. Cheng, 1990, Defective intracellular traffic and processing of CFTR is the molecular basis of most cystic fibrosis, Cell, 63, 827, 10.1016/0092-8674(90)90148-8 · DOI
  66. Zhang, 1998, Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR, Nat Struct Biol, 5, 180, 10.1038/nsb0398-180 · DOI
  67. Kalin, 1999, DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis, J Clin Invest, 103, 1379, 10.1172/JCI5731 · DOI
  68. Penque, 2000, Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells, Lab Invest, 80, 857, 10.1038/labinvest.3780090 · DOI
  69. Andersson, 2000, Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX, Eur Respir J, 15, 937, 10.1034/j.1399-3003.2000.15e21.x · DOI
  70. Rubenstein, 1998, A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelialCFTR function, Am J Respir Crit Care Med, 157, 484, 10.1164/ajrccm.157.2.9706088 · DOI
  71. McCarty, 2002, A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis, Pediatr Pulmonol, 33, 90, 10.1002/ppul.10041 · DOI
  72. Galietta, 2001, Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists, Am J Physiol Cell Physiol, 281, C1734, 10.1152/ajpcell.2001.281.5.C1734 · DOI
  73. Wang, 2000, Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels, J Physiol, 524, 637, 10.1111/j.1469-7793.2000.00637.x · DOI
  74. Knowles, 1990, A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis, N Engl J Med, 322, 1189, 10.1056/NEJM199004263221704 · DOI
  75. Knowles, 1991, Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis, N Engl J Med, 325, 533, 10.1056/NEJM199108223250802 · DOI
  76. Rodgers, 1999, The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis, Eur Respir J, 14, 693, 10.1034/j.1399-3003.1999.14c32.x · DOI
  77. Noone, 2001, Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study, Pediatr Pulmonol, 32, 122, 10.1002/ppul.1098 · DOI
  78. Döring, 2002, Management of infection in cystic fibrosis, Hosp Pharm, 5, 65
  79. Hoiby, 1990, Pseudomonas aeruginosa infection in cystic fibrosis and its management, Thorax, 45, 881, 10.1136/thx.45.11.881 · DOI
  80. Fitzsimmons, 1993, The changing epidemiology of cystic fibrosis, J Pediatr, 122, 1, 10.1016/S0022-3476(05)83478-X · DOI
  81. Szaff, 1982, Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis, Acta Paediatr Scand, 71, 21, 10.1111/j.1651-2227.1982.tb09526.x · DOI
  82. Kahl, 1998, Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis, J Infect Dis, 177, 1023, 10.1086/515238 · DOI · Paper page
  83. Weaver, 1994, Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period, Arch Dis Child, 70, 84, 10.1136/adc.70.2.84 · DOI
  84. Ratjen, 2001, Effect of continuous anti-staphylococcal therapy on the rate of P aeruginosa acquisition in patients with cystic fibrosis, Pediatr Pulmonol, 31, 13, 10.1002/1099-0496(200101)31:1<13::AID-PPUL1001>3.0.CO;2-N · DOI
  85. Stutman, 2002, Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial, J Pediatr, 140, 299, 10.1067/mpd.2002.121930 · DOI
  86. Smyth, 2000, Prophylactic antibiotics for cystic fibrosis (Cochrane Review), Cochrane Database Syst Rev, 2, CD001021
  87. Oliver, 2000, High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection, Science, 288, 1251, 10.1126/science.288.5469.1251 · DOI
  88. Döring, 2000, Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus, Eur Respir J, 16, 749, 10.1034/j.1399-3003.2000.16d30.x · DOI
  89. Barclay, 1996, Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis, J Antimicrob Chemother, 37, 1155, 10.1093/jac/37.6.1155 · DOI
  90. Breen, 2001, Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis, Cochrane Database Syst Rev, 4, CD002767
  91. Frederiksen, 1996, Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment, Pediatr Pulmonol, 21, 153, 10.1002/(SICI)1099-0496(199603)21:3<153::AID-PPUL1>3.0.CO;2-R · DOI
  92. Elborn, 2000, Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs, Thorax, 55, 355, 10.1136/thorax.55.5.355 · DOI
  93. Steinkamp, 1989, Long-term tobramycin inhalation in cystic fibrosis, Pediatr Pulmonol, 6, 91, 10.1002/ppul.1950060207 · DOI
  94. Jensen, 1987, Colistin inhalation therapy in cystic fibrosis patients with chronic P aeruginosa infection, J Antimicrob Chemother, 19, 831, 10.1093/jac/19.6.831 · DOI
  95. Ramsey, 1999, Intermittent administration of inhaled tobramycin in patients with cystic fibrosis, N Engl J Med, 340, 23, 10.1056/NEJM199901073400104 · DOI
  96. Ryan, 2000, Nebulised anti-pseudomonal antibiotics for cystic fibrosis (Cochrane Review), Cochrane Database Syst Rev, 2, CD001021
  97. Kudoh, 1998, Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin, Am J Respir Crit Care Med, 157, 1829, 10.1164/ajrccm.157.6.9710075 · DOI
  98. Jaffe, 1998, Long-term azithromycin may improve lung function in children with cystic fibrosis, Lancet, 351, 420, 10.1016/S0140-6736(05)78360-4 · DOI
  99. Wolter, 2002, Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial, Thorax, 57, 212, 10.1136/thorax.57.3.212 · DOI
  100. Equi, 2002, Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial, Lancet, 360, 978, 10.1016/S0140-6736(02)11081-6 · DOI
  101. Southern, 2000, Macrolide antibiotics for cystic fibrosis (Cochrane Review), Cochrane Database Syst Rev, 3, CD002203
  102. Littlewood, 1985, Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis, Lancet, 1, 865, 10.1016/S0140-6736(85)92222-6 · DOI
  103. Valerius, 1991, Prevention of chronic Pseudomonas aeruginosa colonisation by early treatment, Lancet, 338, 725, 10.1016/0140-6736(91)91446-2 · DOI
  104. Wiesemann, 1998, Placebo-controlled double-blind randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis, Pediatr Pulmonol, 26, 88, 10.1002/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J · DOI
  105. Ratjen, 2001, Eradication of Pseudomonas aeruginosa with inhaled tobramycin in patients with cystic fibrosis, Lancet, 358, 983, 10.1016/S0140-6736(01)06124-4 · DOI
  106. Auerbach, 1985, Alternate-day prednisone reduces morbitity and improves pulmonary function in cystic fibrosis, Lancet, 2, 686, 10.1016/S0140-6736(85)92929-0 · DOI
  107. Eigen, 1995, A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis, J Pediatr, 126, 515, 10.1016/S0022-3476(95)70343-8 · DOI
  108. Lai, 2000, FitzSimmons SC, Allen DB, et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis, N Engl J Med, 342, 851, 10.1056/NEJM200003233421204 · DOI
  109. Cheng, 2000, Oral steroids for cystic fibrosis (Cochrane Review), Cochrane Database Syst Rev, 2, CD000407
  110. Dezateux, 2000, Inhaled corticosteroids for cystic fibrosis (Cochrane Review), Cochrane Database Syst Rev, 2, CD001915
  111. Konstan, 1995, Effect of high-dose ibuprofen in patients with cystic fibrosis, N Engl J Med, 332, 848, 10.1056/NEJM199503303321303 · DOI
  112. McElvaney, 1992, Modulation of airway inflammation in cystic fibrosis: in vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor, J Clin Invest, 90, 1296, 10.1172/JCI115994 · DOI
  113. McElvaney, 1993, Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis, Am Rev Respir Dis, 148, 1056, 10.1164/ajrccm/148.4_Pt_1.1056 · DOI
  114. McElvaney, 1991, Aerosol α 1-antitrypsin treatment for cystic fibrosis, Lancet, 337, 392, 10.1016/0140-6736(91)91167-S · DOI
  115. Cantin, 1999, Aerosolized prolastin suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection, Am J Respir Crit Care Med, 160, 1130, 10.1164/ajrccm.160.4.9807166 · DOI
  116. Ratjen, 1985, A double-blind placebo controlled trial with oral ambroxol and n-acetylcysteine for mucolytic treatment in cystic fibrosis, Eur J Pediatr, 144, 374, 10.1007/BF00441781 · DOI
  117. Fuchs, 1994, Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis, N Engl J Med, 331, 637, 10.1056/NEJM199409083311003 · DOI
  118. Quan, 2001, A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities, J Pediatr, 139, 813, 10.1067/mpd.2001.118570 · DOI
  119. Kearney, 2000, Deoxyribonuclease for cystic fibrosis (Cochrane Review), Cochrane Database Syst Rev, 2, CD001127
  120. Suri, 2001, Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial, Lancet, 358, 1316, 10.1016/S0140-6736(01)06412-1 · DOI
  121. Wark, 2000, Nebulised hypertonic saline for cystic fibrosis (Cochrane Review), Cochrane Database Syst Rev, 2, CD001506
  122. Bennet, 2000, Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT international Registry for Thoracic Organ Transplantation, Clin Transpl, 1, 31
  123. Liou, 2001, Survival effect of lung transplantation among patients with cystic fibrosis, JAMA, 286, 2683, 10.1001/jama.286.21.2683 · DOI
  124. Aurora, 1999, Lung transplantation and life extension in children with cystic fibrosis, Lancet, 354, 1591, 10.1016/S0140-6736(99)03031-7 · DOI
  125. Aris, 2001, Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex: survival linked to genomovar type, Am J Respir Crit Care Med, 164, 2102, 10.1164/ajrccm.164.11.2107022 · DOI
  126. Kerem, 1992, Prediction of mortality in patients with cystic fibrosis, N Engl J Med, 326, 1187, 10.1056/NEJM199204303261804 · DOI · Paper page
  127. Cohen, 2001, Living donor lung transplantation, World J Surg, 25, 244, 10.1007/s002680020025 · DOI
  128. Gaskin, 1982, Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption, J Pediatr, 100, 857, 10.1016/S0022-3476(82)80501-5 · DOI
  129. Corey, 1988, A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto, J Clin Epidemiol, 41, 583, 10.1016/0895-4356(88)90063-7 · DOI
  130. Sinaasappel, 2002, Nutrition in patients with cystic fibrosis: a European consensus, J Cystic Fibrosis, 1, 51, 10.1016/S1569-1993(02)00032-2 · DOI
  131. Smyth, 2000, Oral calorie supplements for cystic fibrosis (Cochrane Review), Cochrane Database Syst Rev, 2, CD000406
  132. Conway, 2000, Enteral tube feeding for cystic fibrosis (Cochrane Review), Cochrane Database Syst Rev, 2, CD001198
  133. Cheng, 2000, Ursodeoxycholic acid for cystic fibrosis-related liver disease (Cochrane Review), Cochrane Database Syst Rev, 2, CD000222
  134. Milkiewicz, 2002, Transplantation for cystic fibrosis: outcome following early liver transplantation, J Gastroenterol Hepatol, 17, 208, 10.1046/j.1440-1746.2002.02671.x · DOI
  135. Fogarthy, 2000, International comparison of median age at death from cystic fibrosis, Chest, 117, 1656, 10.1378/chest.117.6.1656 · DOI
  136. Schechter, 2001, The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States, Am J Respir Crit Care Med, 163, 1331, 10.1164/ajrccm.163.6.9912100 · DOI

Cited by

Sorted by citations

Metadata

Authors
Ratjen, F., & Döring, G.
Venue
The Lancet
Publisher
Elsevier BV
Published
2003-02
Volume
361
Issue
9358
Pages
681-689
ISSN
0140-6736
DOI
10.1016/s0140-6736(03)12567-6
Cited by
885
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review